<DOC>
	<DOCNO>NCT01594983</DOCNO>
	<brief_summary>This study determine dose response signal LCQ908 monotherapy ass efficacy safety add LCQ908 Lovaza fenofibrate .</brief_summary>
	<brief_title>A Pilot Study Assess Efficacy Safety LCQ908 Alone Combination With Fenofibrate Lovaza® Patients With Severe Hypertriglyceridemia</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Male female subject age &gt; 18 year age , inclusive . History plasma TG concentration ≥890 mg/dl ( 10 mmol/L ) history lactescent plasma fast state . Fasting TG ≥ 750 mg/dL ( 8.5 mmol/L ) day 7 repeat day 7 one week later fail qualify initially think likely qualify repeat examination prior randomization . Treatment Omega3 fatty acid niacin fibrates within 8 week screen . Patients confirm Familial Chylomicronemia Syndrome ( FCS ) hyperlipoproteinemia ( HLP ) TypeI diagnosis know homozygote compound heterozygote mutation HLP Type Icausing gene ( LPL , apoCII , CPIHBP1 , LMF1 ) prior screen . Pancreatitis within 3 month prior screen . Uncontrolled type 2 diabetes ( T2DM ) ( define HbA1c value ≥8.0 % screen ) BMI &gt; 40 history bariatric surgery . Nephrotic syndrome , Type 1 diabetes , HIV , HCV HBV positive . Estimated Glomerular Filtration Rate ( eGFR ) &lt; 60 ml/min/1.73m2 Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>hypertriglyceridemia</keyword>
	<keyword>Non familial Chylocmicronemia Syndrome ( non-FCS )</keyword>
</DOC>